Spyre Therapeutics Completes Recruitment for RA Sub-Study of SKYWAY Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy SYRE?
Spyre Therapeutics announced the completion of recruitment for the RA sub-study of the SKYWAY basket trial and acceleration of expected topline readout to Q3 2026. "Enrollment in the RA sub-study of SKYWAY has exceeded our expectations and reflects both substantial unmet need as well as investigator enthusiasm for the potential of a long-acting anti-TL1A antibody," said Joshua Friedman, M.D., Ph.D., SVP of Clinical Development and SKYWAY study lead. "We look forward to delivering the first proof-of-concept data for this mechanism in rheumatic disease in the third quarter, with the potential to advance to pivotal trials next year. Together with readouts from the SKYLINE study, we now expect key data from Spyre's programs in IBD and rheumatic diseases in every subsequent quarter this year."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SYRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SYRE
Wall Street analysts forecast SYRE stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 43.060
Low
40.00
Averages
56.67
High
70.00
Current: 43.060
Low
40.00
Averages
56.67
High
70.00
About SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VR Adviser, LLC Increases Stake in Spyre Therapeutics by 1 Million Shares
- Share Increase: On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1 million shares of Spyre Therapeutics, with an estimated trade value of $25.78 million based on quarterly average pricing, indicating strong confidence in the biotech firm.
- Value Growth: As of December 31, 2025, VR Adviser's total holding in Spyre Therapeutics reached $120.74 million, reflecting an increase of $75.73 million from the previous quarter, driven by both trading activity and share price appreciation.
- Portfolio Significance: Spyre Therapeutics now represents 5.96% of VR Adviser's 27-position U.S. equity portfolio, highlighting its importance within the fund, particularly under a strategy focused on biotechnology investments.
- Market Competitiveness: As a preclinical-stage biotechnology company, Spyre Therapeutics specializes in developing novel antibody therapies for inflammatory bowel disease, aiming to address significant unmet medical needs in gastrointestinal health, which positions it for long-term value creation.
See More
VR Adviser Increases Stake in Spyre Therapeutics by 1 Million Shares
- Share Acquisition: On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1 million shares in Spyre Therapeutics, valued at approximately $25.78 million, reflecting the firm's confidence in the biotech company.
- Value Appreciation: As of December 31, 2025, VR Adviser's total holdings in Spyre reached 3,685,448 shares, valued at $120.74 million, with a quarter-end increase of $75.73 million, showcasing the dual impact of share price appreciation and trading activity.
- Portfolio Significance: Spyre Therapeutics now represents 5.96% of VR Adviser's reportable U.S. equity assets, highlighting its strategic importance within the firm's 27-position portfolio in the biotech sector.
- Strong Market Performance: As of March 18, 2026, Spyre's share price stood at $43.03, reflecting a 132.1% increase over the past year, significantly outperforming the S&P 500 by 115.4%, indicating robust market performance and investment appeal.
See More
VR Adviser, LLC Reduces Stake in Ocular Therapeutix
- Share Reduction Details: On February 17, 2026, VR Adviser, LLC disclosed the sale of 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $70.96 million, indicating a potential decline in confidence in the stock.
- Asset Management Impact: This transaction reduced Ocular Therapeutix's share of VR Adviser's reportable assets under management to 4.39%, with a holding value of $88.81 million, reflecting a diminished significance in the fund's portfolio.
- Market Performance Analysis: As of February 17, 2026, Ocular Therapeutix shares were priced at $6.99, down 3.98% over the past year, underperforming the S&P 500 by 15.90 percentage points, suggesting low market expectations for future growth.
- Investor Considerations: While the reduction is a routine portfolio management action, Ocular Therapeutix's product DEXTENZA and its drug delivery technology offer differentiation in a competitive ophthalmology market, warranting investor attention on its future market expansion and revenue growth potential.
See More
VR Adviser, LLC Sells Shares of Ocular Therapeutix
- Share Sale Overview: On February 17, 2026, VR Adviser, LLC disclosed to the SEC that it sold 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $71.01 million, reducing its stake in the company to 4.4%.
- Asset Management Impact: The sale resulted in a $65.05 million decrease in the value of VR Adviser's position, highlighting the direct impact of trading and stock price fluctuations on its assets under management during the fourth quarter.
- Portfolio Adjustment: This transaction represented 3.51% of VR Adviser's reportable assets under management, indicating routine portfolio management adjustments within its strategy of concentrated investments in small-cap biotech firms.
- Market Performance Analysis: Ocular Therapeutix's stock has declined approximately 4% over the past year and has underperformed the S&P 500 by about 16 points, reflecting uneven growth in a competitive ophthalmic pharmaceutical market, which may affect investor confidence.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
VR Adviser, LLC Increases Stake in Spyre Therapeutics by 1 Million Shares
- Share Increase: On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1 million shares of Spyre Therapeutics, with an estimated trade value of $25.78 million based on quarterly average pricing, indicating strong confidence in the biotech firm.
- Value Growth: As of December 31, 2025, VR Adviser's total holding in Spyre Therapeutics reached $120.74 million, reflecting an increase of $75.73 million from the previous quarter, driven by both trading activity and share price appreciation.
- Portfolio Significance: Spyre Therapeutics now represents 5.96% of VR Adviser's 27-position U.S. equity portfolio, highlighting its importance within the fund, particularly under a strategy focused on biotechnology investments.
- Market Competitiveness: As a preclinical-stage biotechnology company, Spyre Therapeutics specializes in developing novel antibody therapies for inflammatory bowel disease, aiming to address significant unmet medical needs in gastrointestinal health, which positions it for long-term value creation.
See More
VR Adviser Increases Stake in Spyre Therapeutics by 1 Million Shares
- Share Acquisition: On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1 million shares in Spyre Therapeutics, valued at approximately $25.78 million, reflecting the firm's confidence in the biotech company.
- Value Appreciation: As of December 31, 2025, VR Adviser's total holdings in Spyre reached 3,685,448 shares, valued at $120.74 million, with a quarter-end increase of $75.73 million, showcasing the dual impact of share price appreciation and trading activity.
- Portfolio Significance: Spyre Therapeutics now represents 5.96% of VR Adviser's reportable U.S. equity assets, highlighting its strategic importance within the firm's 27-position portfolio in the biotech sector.
- Strong Market Performance: As of March 18, 2026, Spyre's share price stood at $43.03, reflecting a 132.1% increase over the past year, significantly outperforming the S&P 500 by 115.4%, indicating robust market performance and investment appeal.
See More
VR Adviser, LLC Reduces Stake in Ocular Therapeutix
- Share Reduction Details: On February 17, 2026, VR Adviser, LLC disclosed the sale of 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $70.96 million, indicating a potential decline in confidence in the stock.
- Asset Management Impact: This transaction reduced Ocular Therapeutix's share of VR Adviser's reportable assets under management to 4.39%, with a holding value of $88.81 million, reflecting a diminished significance in the fund's portfolio.
- Market Performance Analysis: As of February 17, 2026, Ocular Therapeutix shares were priced at $6.99, down 3.98% over the past year, underperforming the S&P 500 by 15.90 percentage points, suggesting low market expectations for future growth.
- Investor Considerations: While the reduction is a routine portfolio management action, Ocular Therapeutix's product DEXTENZA and its drug delivery technology offer differentiation in a competitive ophthalmology market, warranting investor attention on its future market expansion and revenue growth potential.
See More
VR Adviser, LLC Sells Shares of Ocular Therapeutix
- Share Sale Overview: On February 17, 2026, VR Adviser, LLC disclosed to the SEC that it sold 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $71.01 million, reducing its stake in the company to 4.4%.
- Asset Management Impact: The sale resulted in a $65.05 million decrease in the value of VR Adviser's position, highlighting the direct impact of trading and stock price fluctuations on its assets under management during the fourth quarter.
- Portfolio Adjustment: This transaction represented 3.51% of VR Adviser's reportable assets under management, indicating routine portfolio management adjustments within its strategy of concentrated investments in small-cap biotech firms.
- Market Performance Analysis: Ocular Therapeutix's stock has declined approximately 4% over the past year and has underperformed the S&P 500 by about 16 points, reflecting uneven growth in a competitive ophthalmic pharmaceutical market, which may affect investor confidence.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
